ConductScience.org, home

Paper31360201

Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages.

Lu D and 6 others. Arch Med Sci, 2019. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages. Papers, record 31360201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31360201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages.
PubMed
Journal
Arch Med Sci
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.85
iCite
Revised in PubMed
2022-04-09
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lu DDan
2Peng FFen
3Li JJun
4Zhao JJing
5Ye XXiaojin
6Li BBinghan
7Ding WWenhui

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111884288Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice.Arterioscler Thromb Vasc Biol2002https://conductscience.org/library/papers/11884288PubMed
214702425Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.N Engl J Med2004https://conductscience.org/library/papers/14702425PubMed
315322539The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.Nat Med2004https://conductscience.org/library/papers/15322539PubMed
415618545Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells.Arterioscler Thromb Vasc Biol2005https://conductscience.org/library/papers/15618545PubMed
516041318Leukotriene modifiers as potential therapeutics for cardiovascular disease.Nat Rev Drug Discov2005https://conductscience.org/library/papers/16041318PubMed
616172428Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages.Hypertension2005https://conductscience.org/library/papers/16172428PubMed
716343502Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells.Atherosclerosis2006https://conductscience.org/library/papers/16343502PubMed
817261470Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension.Am J Hypertens2007https://conductscience.org/library/papers/17261470PubMed
917617581Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes.J Immunol2007https://conductscience.org/library/papers/17617581PubMed
1017761955NADPH oxidase deficiency results in reduced alveolar macrophage 5-lipoxygenase expression and decreased leukotriene synthesis.J Leukoc Biol2007https://conductscience.org/library/papers/17761955PubMed
1118039117Inflammation and atherosclerosis.Annu Rev Pathol2006https://conductscience.org/library/papers/18039117PubMed
1218338983Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.Clin Sci (Lond)2008https://conductscience.org/library/papers/18338983PubMed
1319199921Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases.Curr Med Chem2009https://conductscience.org/library/papers/19199921PubMed
1420093252The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.Cardiovasc Res2010https://conductscience.org/library/papers/20093252PubMed
1520416349Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway.Peptides2010https://conductscience.org/library/papers/20416349PubMed
1620554538HNE-induced 5-LO expression is regulated by NF-{kappa}B/ERK and Sp1/p38 MAPK pathways via EGF receptor in murine macrophages.Cardiovasc Res2010https://conductscience.org/library/papers/20554538PubMed
17216911425-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion.Exp Mol Med2011https://conductscience.org/library/papers/21691142PubMed
1822380002Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages.Pharmacogenomics2012https://conductscience.org/library/papers/22380002PubMed
1922956414Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease.Curr Atheroscler Rep2012https://conductscience.org/library/papers/22956414PubMed
2023053343Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations.Heart Vessels2013https://conductscience.org/library/papers/23053343PubMed

See all 22 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42410254Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation.Calcif Tissue Int2026https://conductscience.org/library/papers/42410254PubMed
42305333The impact of diffuse large B-cell lymphoma-derived exosomes on macrophage polarisation and cytokine release.Arch Med Sci2026https://conductscience.org/library/papers/42305333PubMed
40707413Urotensin II system contributes to ischemic acute kidney injury in neonatal pigs.Ren Fail2025https://conductscience.org/library/papers/40707413PubMed
39596935Elevated Urotensin-II and TGF-β Levels in COPD: Biomarkers of Fibrosis and Airway Remodeling in Smokers.Medicina (Kaunas)2024https://conductscience.org/library/papers/39596935PubMed
39341842The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male mice.Nat Commun2024https://conductscience.org/library/papers/39341842PubMed
39050164Network analysis of the effects of long non-coding RNAs in artemisinin treatment of atherosclerosis in APOE-/- mice.Arch Med Sci2024https://conductscience.org/library/papers/39050164PubMed
36835230Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits.Int J Mol Sci2023https://conductscience.org/library/papers/36835230PubMed
36518054Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-α induced by urotensin II.J Zhejiang Univ Sci B2022https://conductscience.org/library/papers/36518054PubMed
36188724Urotensin II level is elevated in inflammatory bowel disease patients.World J Gastroenterol2022https://conductscience.org/library/papers/36188724PubMed
35174439The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.J Cell Commun Signal2022https://conductscience.org/library/papers/35174439PubMed
33732368Salidroside and isorhamnetin attenuate urotensin II-induced inflammatory response in vivo and in vitro: Involvement in regulating the RhoA/ROCK II pathway.Oncol Lett2021https://conductscience.org/library/papers/33732368PubMed
32362652Oridonin Alleviates IRI-Induced Kidney Injury by Inhibiting Inflammatory Response of Macrophages via AKT-Related Pathways.Med Sci Monit2020https://conductscience.org/library/papers/32362652PubMed
31754613Tanshinone IIA attenuates Aβ-induced neurotoxicity by down-regulating COX-2 expression and PGE2 synthesis via inactivation of NF-κB pathway in SH-SY5Y cells.J Biol Res (Thessalon)2019https://conductscience.org/library/papers/31754613PubMed
31520306Early and Sustained Increases in Leukotriene B4 Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients.Neurotherapeutics2020https://conductscience.org/library/papers/31520306PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
UTS210911PubTator's text mininghttps://conductscience.org/library/genes/10911NCBI Gene
UTS2R2837PubTator's text mininghttps://conductscience.org/library/genes/2837NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31360201

GET https://conductscience.org/api/papers/v1/31360201/references?page=2